TriangleHEALTH PROFESSIONAL · SOURCE READING
Immunophenotype
Source: Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Relapsed Childhood ALL / Prognostic Factors After First Relapse of Childhood ALL
Immunophenotype is an important prognostic factor at relapse. Patients with T-ALL tend to experience earlier relapses than noninfant patients with B-ALL. In a study from the COG, the median time to relapse was 13.8 months for patients with T-ALL, compared with 34.6 months for noninfant patients with B-ALL. The 5-year postrelapse OS rate was only 35% for those with T-ALL, compared with 52.5% for noninfant patients with B-ALL.[15] Patients with T-ALL are less likely to achieve a second remission after relapse than those with B-ALL.[5,24]
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice